Small Molecules
23 February 2016
Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings22 February 2016
Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain22 February 2016
Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer19 February 2016
Naldemedine Phase 3 Study Shows Significant Improvement for Patients with Opioid-Induced Constipation19 February 2016
U.S. FDA approves UCB’s new epilepsy treatment, BRIVIACT®, for patients with partial-onset seizures19 February 2016
Strategia Therapeutics Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent “FF-10502″ For FUJIFILM in Patients with Advanced Cancers19 February 2016
Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack18 February 2016
Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS17 February 2016
Tonix Pharmaceuticals Reports Top Line Results From Phase 2 Proof-of-Concept Clinical Study of TNX-201 in Episodic Tension-Type Headache17 February 2016
Flexion Therapeutics Reports Primary Endpoint Met in Pivotal Phase 3 Trial of Zilretta™ in Knee Osteoarthritis16 February 2016
Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers16 February 2016
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO® (ceftaroline fosamil)16 February 2016
U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease16 February 2016
Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)11 February 2016
Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer’s Disease11 February 2016
Atlantic Healthcare starts pivotal Phase 3 trial of Alicaforsen to treat Inflammatory Bowel Disease Pouchitis11 February 2016
Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor10 February 2016
AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with EndometriosisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports